Therapeutic Asset Ratings

223 results matching 1 filter

128,359 assets · 8,667 sponsors · 3,127 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Benmelstobart renal cell carcinoma	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
Calcium folinate pentahydrate Conversion Therapy	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
Capecitabine Colorectal Cancer Liver Metastases (CRLM)	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
Carboplatin EGFR Mutation	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
Carboplatin Furmonertinib	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
Catequentinib Aumolertinib	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
Catequentinib EGFR Activating Mutation	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
Catequentinib Recurrent/Refractory Classical Hodgkin's Lymphoma	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
Catequentinib childhood malignant neoplasm	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
Catequentinib Li-Fraumeni syndrome	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
Cetuximab Dabrafenib	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
Cetuximab Ipilimumab N01	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
Cetuximab MSS (Microsatellite Stable)	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
Cetuximab Sintilimab	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE Extra-nodal Involvement, Large Mass	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
CIS-DIAMMINEDICHLOROPLATINUM II Colorectal Cancer Liver Metastases (CRLM)	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
CIS-DIAMMINEDICHLOROPLATINUM II Immune Checkpoint Inhibitors	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
CIS-DIAMMINEDICHLOROPLATINUM II Liver Metastasis	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
CIS-DIAMMINEDICHLOROPLATINUM II QL1706	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
Cyclophosphamide Extra-nodal Involvement, Large Mass	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
Cyclophosphamide Immune Checkpoint Inhibitors	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
Cyclophosphamide QL1706	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
Dabrafenib BRAF V600E	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
Dabrafenib Cetuximab	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)
Dabrafenib Dabrafenib	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (53)

Showing 76 to 100 of 223 assets

PreviousPage 4 of 9Next